SGN-30 Seattle Genetics

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 2, 2006, Pages 164-172

  Schnell, Roland ^a   Borchmann, Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHIMERIC ANTIBODY; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MDX 060; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M44; MONOCLONAL ANTIBODY M67; NAVELBINE; PREDNISONE; PROCARBAZINE; RECOMBINANT ANTIBODY; SGN 30; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ANAPLASTIC CARCINOMA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER IMMUNOTHERAPY; CATHETER INFECTION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; EUROPE; FATIGUE; FOOT EDEMA; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; IMMUNOPATHOLOGY; INSOMNIA; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NOSE CONGESTION; PATENT; PNEUMONIA; PRURITUS; REVIEW; SKIN LYMPHOMA; SKIN MANIFESTATION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

HERPES ZOSTER;

EID: 33645722037     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. 47 Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Gruss HJ, Dower SK BLOOD 1995 85 12 3378-3404
2. 41 Treatment of refractory Hodgkin's disease with an antiCD16/CD30 bispecific antibody. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, KJoft M, Pfreundschuh M BLOOD 1997 89 6 2042-2047
3. 17 Seattle Genetics mAbs for cancer: Lead agents. Seattle Genetics Inc COMPANY WORLD WIDE WEBSITE 2000 December 18
4. 12 Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, Konig J, Bauer S, Kloft M, Pfreundschuh M CLIN CANCER RES 20017 7 1873-1881
5. 54 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C N ENGL J MED 2002 346 4 235-242
6. 37 SGN-30, a chimeric antibody to CD30, for the treatment of Hodgkin's disease. Wahl AF, Cerveny CH, Klussman K, Chen JH, Francisco LV, Thompson JD, Chace DF, Siegall CB, Francisco JA PROC AM ASSOC CANCER RES 2002 43 Abs 4979
7. 12 The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Wahl AF, Kussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA CANCER RES 2002 62 13 3736-3742
8. 54 Seattle Genetics advances SGN-30 to multi-dose phase I/II clinical trial, provides update on SGN-15 and closes its SGN-10 clinical program. Seattle Genetics Inc PRESS RELEASE 2002 November 07
9. 64 Phase I study of SGN-30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies. Bartlett NL, Younes A, Carabasi MA, Espina B, DiPersio JF, Schliebner SD, Siegall C, Sing AP BLOOD 2002 100 11 Abs1403
10. 05 Pharmacokinetics, safety, and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies. Carabasi MA, Bartlett NL, Younes A, Miller DM, Schliebner SD, Siegall CB, Sing AP PROC AM SOC CLIN ONCOL 2003 22 Abs722
11. 62 Seattle Genetics receives Orphan Drug designation from the FDA for SGN-30. Seattle Genetics Inc PRESS RELEASE 2003 July 28
12. 06 Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies. Bartlett NL, Bernstein SH, Leonard JP, Rosenblatt JD, Younes A, Carabasi MH, Bociek RG, Forero A, Miller D, Siegall CB, Sing AP BLOOD 2003 102 11 Abs 2390
13. 37 Seattle Genetics announces manufacturing agreement with Abbott Laboratories. Seattle Genetics Inc PRESS RELEASE 2004 February 24
14. 44 Seattle Genetics receives orphan drug designation for SGN-30 in T-cell lymphomas. Seattle Genetics Inc PRESS RELEASE 2004 February 26
15. 14 Hodgkin's disease growth inhibition and sensitization to standard chemotherapeutics by the anti-CD30 monoclonal antibody SGN-30. Cerveny CG, Law CL, Klussman K, Westendorf LE, Petroziello JM, Hamblett KJ, Francisco A Wahl AF PROC AM ASSOC CANCER RES 2004 45 Abs 2258
16. 00 Monoclonal Antibodies in Cancer - Fourth International Congress (Part I), Colorado Springs, CO, USA. Horak ID IDDB MEETING REPORT 2004 September 03-06
17. 65 Phase II study of SGN-30 (Anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin's disease. Leonard JP, Rosenblatt JD, Bartlett NL, Gopal A, Younes A, Fisher D, Foss F, Forero A, Bernstein S, Cheson B, Carabasi MH, Bociek RG, Hart B, McDonald M BLOOD 2004 104 11 Abs 2635
18. 67 SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Forero-Torres A, Bernstein S, Gopal A, Foss F, Leonard J, Rosenblatt J, Bartlett N, Younes A, Fisher D, Cheson B, Carabasi M, Bociek G, Hart B, McDonald M BLOOD 2004 104 11 Abs 2637
19. 69 The anti-CD30 monoclonal antibody SGN-30 inhibits Hodgkins disease growth and sensitizes cells to established chemotherapeutics. Cerveny CG, Law C-L, McCormick RS, Lenox JS, Hambleft KJ, Westendorf LE, Yamane AK, Petroziello JM, Francisco A Wahl AF BLOOD 2004 104 11 Abs 2639
20. 44 SGN-30, a novel chimeric anti-CD30 antibody, Induces cell cycle arrest and apoptosis In ALK+ anaplastic large cell lymphoma. Valbuena JR, Atwell C, Georgakis GV, Younes A, Medeiros LJ, Rassidakis GZ PROC AM ASSOC CANCER RES 2005 46 Abs 449
21. 65 Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30. Leonard JP, Younes A, Rosenblatt JD, Gopal A, Pinter-Brown LC, Bartlett NL, Burns LJ, Forero, A, Barton J PROC AM SOC CLIN ONCOL 2005 24 Abs 2553
22. 72 Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients wilth refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Forero A, Bernstein S, Gopal A, Foss F, Leonard J, Bartlett N, Cheson B, Barton J PROC AM SOC CLIN ONCOL 2005 24 Abs 6601
23. 66 Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V NATURE 1982 299 5878 65-67
24. 67 CD30 in normal and neoplastic cells. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G CLIN IMMUNOL 1999 90 2 157-164
25. 68 CD30: expression and function in health and disease. Horie R, Watanabe T SEMIN IMMUNOL 1998 10 6 457-470
26. 70 Reverse signaling via CD30 ligand. Wley SIR, Goodwin RG, Smith CA J Immunol 1996 167 8 3635-3639
27. 77 CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Hubinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, Sigg I, Graf J, Bergmann L ONCOGENE 2001 20 5 590-598
28. 87 Pleiotropic effects of the CD30 ligand on C1330-expressing cells and lymphoma cell lines. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG BLOOD 1994 83 8 2045-2056
29. 91 The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A BLOOD 2003 102 10 3737-3742
30. 93 Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Mir SS, Richter BW, Duckett CS BLOOD 2000 96 13 4307-4312
31. 95 Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin ME, Watanabe T ONCOGENE 2002 21 16 2493-2503
32. 35 Preliminary phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with cutaneous anaplastic large cell lymphoma (ALCL). Duvic M, Kunishige J, Kim YH, Foreno-Torres A, Pinter-Brown LC, Rarick MU, Zic J, Worobec SM, Foss F, Flessland K, Barton J BLOOD 2005 106 11 Abs 4802
33. 75 SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Forero-Torres A, Bernstein S, Gopal AK, Foss F, Leonard JP, Rosenblatt J, Bartlett N, Cheson B, Epnerb E, Proctor S, Barton J BLOOD 2005 106 11 Abs 3356
34. 35 The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K BLOOD 1985 66 4 848-858
35. 36 Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. Hecht TT, Longo DL, Cossman J, Bolen JB, Hsu SM, Israel M, Fisher RI J IMMUNOL 1985 134 6 4231-4236
36. 39 CD30 expression is common in mediastinal large B-cell lymphoma. Higgins JP, Warnke RA AM J CLIN PATHOL 1999 112 2 241-247
37. 42 CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. Leroy X, Augusto D, Leteurtre E, Gosselin B J HISTOCHEM CYTOCHEM 2002 60 2 283-285
38. 44 CD30+ anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Stein H, Foss HID, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B BLOOD 2000 96 12 3681-3695
39. 46 Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Ralfkiaer E, Bosq J, Gatter KC, Schwarting R, Gerdes J, Stein H, Mason DY ARCH DERMATOL 1987 279 5 285-292
40. 68 Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFκB activation. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T J BIOL CHEM 1997 272 4 2042-2045
41. 69 Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T, Higashihara M, Kadin M, Watanabe T AM J PATHOL 2002 160 5 1647-1654
42. 72 A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Pfeifer W, Levi E, Petrogiannis-Haliotis T, Lehmann L, Wang Z, Kadin ME AM J PATHOL 1999 166 4 1353-1359
43. 74 In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Tian ZG, Longo DL, Funakoshi S, Asai O, Ferris DK, Widmer M, Murphy WJ CANCER RES 1995 56 22 5335-5341
44. 76 Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Durkop H, Averse F, Corneli P, Pizzolo G et al LANCET 1992 339 8803 1195-1196
45. 77 A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A CLIN CANCER RES 2002 8 6 1779-1786
46. 84 Treatment of refractory Hodgkin's lymphoma patients with an iodine-131 -labeled murine anti-CD30 monoclonal antibody. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A J CLIN ONCOL 2005 23 21 4669-4678
47. 64 Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER J IMMUNOL 1993 151 11 5896-8906
48. 91 Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, Yamane AK, Petroziello JM, Francisco JA, Wahl AF LEUKEMIA 2005 19 9 1648-1655
49. 06 Disseminated growth of Hodgkin's-derived cell lines L540 and L640cy in immune-deficient SCID mice. Kapp U, Dux A, Schell-Frederick E, Banik N, Hummel M, Mucke S, Fonatsch C, Bullerdiek J, Gottstein C, Engert A et al ANN ONCOL 1994 5 Suppi 1 121-126
50. 26 Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry. Ye H, Wu H PROC N4TL ACAD SCI USA 2000 97 6 8961-8966
51. 30 High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Everdeen DS, Alber T, Crute JJ, Kehry MR BIOCHEMISTRY 1999 38 31 10168-10177
52. 40 Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, von Strandmann EP J IMMUNOTHER 2004 27 5 347 353
53. 44 Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: Rationale, background studies, and recent results. Bonadonna G, Santoro A, Bonfante V, Valagussa P CANCER TREAT REP 1982 66 4 881-887
54. 49 BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M J CLIN ONCOL 1998 16 12 3810-3821
55. 51 Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A ANN ONCOL 2005 16 1 116-123
56. 78 CD30+ T cells in rheumatoid synovitis: Mechanisms of recruitment and functional role. Gerli R, Pitzalis C, Bistoni O, Falini B, Costantini V, Russano A, Lunardi C J IMMUNOL 2000 164 8 4399-4407
57. 81 Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. Ihn H, Yazawa N, Kubo M, Yamane K, Sato S, Fujimoto M, Kikuchi K, Soma Y, Tamaki K J RHEUMATOL 2000 27 3 698-702
58. 88 Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A BLOOD 2002 100 9 3101-3107
59. 59 Current treatment and immunotherapy of Hodgkin's lymphoma. Klimm B, Schnell R, Diehl V, Engert A HAEMATOLOGICA 2005 90 12 1680-1692
60. 04 Significance of minimal residual disease in lymphoid malignancies. Bruggemann M, Pott C, Ritgen M, Kneba M ACTA HAEMATOL 2004 112 1-2 111-119
61. 11 Expression of the CD30 antigen in non-lymphoid tissues and cells. Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, Stein H J PATHOL 2000 190 5 613-618
62. 23 Antitumour activity of a chimeric antibody against the leucocyte antigen CD48. Sun H, Biggs JC, Smith GM CANCER IMMUNOL IMMUNOTHER 2000 48 10 595-602
63. 65 SGN-30. Seattle Genetics Inc COMPANY COMMUNICATION 2006 March 17